Trials / Recruiting
RecruitingNCT06232265
An Observational Study on Predicting the Efficacy of Immunotherapy for NSCLC Based on LIRAscore
An Observational Study on Predicting the Efficacy of Immunotherapy for Non-small-cell Lung Cancer Based on LIRAscore
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 108 (estimated)
- Sponsor
- Nanfang Hospital, Southern Medical University · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This is a multi-center, observational clinical study to explore the role of LIRAscore in predicting immunotherapy monotherapy and combination with chemotherapy efficacy and prognosis in locally advanced or metastatic non-small-cell lung cancer. The study plans to enroll 108 patients. The primary endpoint of this study was ORR, and secondary endpoints were PFS, OS, DoR, DCR, and safety.
Conditions
Timeline
- Start date
- 2023-09-22
- Primary completion
- 2025-08-01
- Completion
- 2026-08-01
- First posted
- 2024-01-30
- Last updated
- 2024-01-30
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06232265. Inclusion in this directory is not an endorsement.